Status:
TERMINATED
Saved From COVID-19 - Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID
Lead Sponsor:
Columbia University
Conditions:
COVID
Coronavirus Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The primary objective is to determine the clinical efficacy of Chloroquine (CQ) in health care workers with moderate to high risk of exposure to COVID-19 in preventing symptomatic COVID-19 infections....
Detailed Description
Chloroquine (CQ) phosphate is an immunomodulatory drug that has been approved by the FDA for prophylaxis of and treatment of malaria, treatment of lupus erythematosus, and treatment of rheumatoid arth...
Eligibility Criteria
Inclusion
- Age ≥18 years,
- Employment by New York Presbyterian Hospital
- Clear assignment to areas of the hospital that involve patient contact and possible exposures for at least 2 days a week \>/= 8 hours a day
Exclusion
- Individuals who are taking CQ for other indications
- New use of NSAIDs
- High risk background medications not limited to immunosuppressive regimens, steroids, anti-B cell therapies, anti-cytokine therapies, chemotherapies, Janus Kinase (JAK)-inhibitors
- Individuals with a history of retinopathy that would contraindicate the use of CQ
- Known allergy to CQ or chloroquine
- Known QT prolongation and torsades de point
- Individuals who are pregnant or nursing
Key Trial Info
Start Date :
April 21 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 11 2021
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT04349371
Start Date
April 21 2020
End Date
February 11 2021
Last Update
February 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Columbia University Irving Medical Center/NYP
New York, New York, United States, 10032